| Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling G Zimmermann, B Papke, S Ismail, N Vartak, A Chandra, M Hoffmann, ... Nature 497 (7451), 638-642, 2013 | 688 | 2013 |
| Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ... Nature medicine 25 (4), 628-640, 2019 | 562 | 2019 |
| Drugging RAS: Know the enemy B Papke, CJ Der Science 355 (6330), 1158-1163, 2017 | 377 | 2017 |
| KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport M Schmick, N Vartak, B Papke, M Kovacevic, DC Truxius, L Rossmannek, ... Cell 157 (2), 459-471, 2014 | 258 | 2014 |
| Identification of pyrazolopyridazinones as PDEδ inhibitors B Papke, S Murarka, HA Vogel, P Martín-Gago, M Kovacevic, DC Truxius, ... Nature communications 7 (1), 11360, 2016 | 165 | 2016 |
| Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ... Cancer discovery 10 (1), 104-123, 2020 | 153 | 2020 |
| The autodepalmitoylating activity of APT maintains the spatial organization of palmitoylated membrane proteins N Vartak, B Papke, HE Grecco, L Rossmannek, H Waldmann, C Hedberg, ... Biophysical journal 106 (1), 93-105, 2014 | 94 | 2014 |
| Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ... Cell reports 31 (11), 2020 | 75 | 2020 |
| Precise measurement of protein interacting fractions with fluorescence lifetime imaging microscopy KA Walther, B Papke, MB Sinn, K Michel, A Kinkhabwala Molecular Biosystems 7 (2), 322-336, 2011 | 51 | 2011 |
| Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ... Cancer research 83 (1), 141-157, 2023 | 37 | 2023 |
| Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ... Cancer research 82 (4), 586-598, 2022 | 28 | 2022 |
| Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ... Cell reports 35 (13), 2021 | 18 | 2021 |
| CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ... Cell reports 37 (9), 2021 | 17 | 2021 |
| The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ... Journal of Biological Chemistry 297 (5), 2021 | 16 | 2021 |
| Silencing of oncogenic KRAS by mutant-selective small interfering RNA B Papke, SH Azam, AY Feng, C Gutierrez-Ford, H Huggins, PS Pallan, ... ACS Pharmacology & Translational Science 4 (2), 703-712, 2021 | 13 | 2021 |
| Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ... Nature medicine 26 (6), 982-982, 2020 | 5 | 2020 |
| Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer CM Goodwin, S Javaid, AM Waters, B Papke, R Yang, M Pierobon, ... Cancer Research 79 (13_Supplement), LB-287-LB-287, 2019 | 2 | 2019 |
| the spatial organization of Ras signaling B Papke, M Schmick, N Vartak, PIH Bastiaens Ras Superfamily Small G Proteins: Biology and Mechanisms 1: General Features …, 2014 | 2 | 2014 |
| Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA B Papke, AED Van Swearingen, AY Feng, SH Azam, EB Harrison, R Yang, ... Molecular Cancer Research 18 (5_Supplement), B32-B32, 2020 | 1 | 2020 |
| Eine neue Ära der Tumortherapie: RAS-Proteine als pharmakologische Targets B Papke, C Sers PHARMAKON 12 (2), 114-120, 2024 | | 2024 |
